

Topic


- Cases and Deaths
- Case Rates
- Death Rates
- Syndromes
- Serotypes
- Antibiotic Resistance
- Surveillance Report


Year

2022

Dataset version: Jun 2024
Final run: Jul 5, 2024

Note: Click [here](#) to access and download Surveillance Reports.

 [Data Download](#)

Group A *Streptococcus* (GAS) Group B *Streptococcus* (GBS) *Haemophilus influenzae* (HFlu) *Neisseria meningitidis* (NMen) *Streptococcus pneumoniae* (SPN) Bact Facts 

**Active Bacterial Core Surveillance (ABCs) Report
Emerging Infections Program Network
Streptococcus pneumoniae, 2022**

ABCs Areas: California (3 county San Francisco Bay area); Colorado (5 county Denver area); Connecticut; Georgia (20 county Atlanta area); Maryland (6 county Baltimore area); Minnesota; New Mexico; New York (15 county Rochester and Albany areas and children <5 years in Erie county); Oregon (3 county Portland area); Tennessee (20 counties).

ABCs Population: The surveillance areas represent 35,040,342 persons. Source: Census Bureau's Vintage 2022 population estimates.

ABCs Case Definition: Disease is defined as isolation of *S. pneumoniae* from a normally sterile site or detection of pathogen-specific nucleic acid in a specimen obtained from a normally sterile body site, using a validated molecular test in a resident of one of the surveillance areas.

ABCs Methodology: ABCs personnel routinely contacted microbiology laboratories serving acute care hospitals to identify cases. Standardized case report forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified case. Whole genome sequencing (WGS) based characterization was conducted on all pneumococcal isolates, which includes deduction of capsular serotype and minimum inhibitory concentration (MIC) predictions (including PBP typing system for determining beta lactam antibiotic MICs). Conventional MIC testing is conducted on selected strains. Regular laboratory audits assessed completeness of active surveillance and detected additional cases.

Rates of invasive pneumococcal disease were calculated using population estimates from the Vintage 2022 file. For national estimates, race- and age-specific rates of disease were applied from the aggregate surveillance area to the age and racial distribution of the U.S. population. Cases with missing data, excluding ethnicity, were multiply imputed using sequential regression imputation methods.¹

ABCs Profiles

Race	No.	Rate*
Black	707	12.1
White	1,959	7.9
Other	255	5.7

Age (years)	Cases		Deaths	
	No.	Rate*	No.	Rate*
<1	42	10.8	2	0.52
1	29	7.6	0	0.00
2-4	81	6.8	4	0.34
5-17	126	2.3	6	0.11
18-34	250	3.1	17	0.21
35-49	517	7.4	39	0.56
50-64	884	13.2	118	1.78
65-74	536	15.8	59	1.73
75-84	279	16.4	46	2.70
≥85	176	27.5	48	7.49
Total	2,920	8.3	340	0.97

*Rates are per 100,000 population for ABCs areas

Surveillance Note

Missing race (n=223) data were multiply imputed using sequential regression imputation methods.

Citation

Centers for Disease Control and Prevention. 2022. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2022.

Antibiotic Susceptibility

Antibiotic	S*	I†	R‡
TMPsulfa	78.4	15.2	6.4
Erythromycin	73.8	0.3	25.8
Levofloxacin	100.0	0.0	0.0
Penicillin+	96.2	1.2	2.3
Cefotaxime	96.4	1.5	0.2
Tetracycline	89.6	0.0	10.4
Vancomycin	100.0	0.0	0.0

Based on reference lab testing of 2,429 isolates.
*Susceptible; †Intermediate; ‡Resistant based on 2022 CLSI definitions. +Penicillin CLSI breakpoints changed in 2009.

National Estimates of Invasive Disease

Total Cases: 27,770 (8.3/100,000 population)
Deaths: 3,230 (0.97/100,000 population)

Syndromes

Syndrome	No.	%*
Meningitis	230	7.9
Bacteremia Without Focus	385	13.2
Bacteremia With Pneumonia	2,065	70.7

*Percent of Cases